Based on decades of novel research, Apex Bio is developing a ground–breaking approach, targeting Amyloid-β oligomers for early theragnostics of Alzheimer’s disease before symptoms even begin.
Founded in 2025, Apex Bio is an Israeli biotech startup developing a ground-breaking approach—based on novel research—targeting Amyloid-β oligomers for early theragnostic of Alzheimer’s disease.
At Apex Bio, we’re rewriting the future of brain health. Our novel platform can diagnose, prevent, and reverse up to 40 conditions, including neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS, and many others—before symptoms even begin.
Alzheimer’s disease is marked by brain atrophy and loss of neurons, neuronal processes, and synapses. Studies indicate the root cause lies in the aggregation of Amyloid-β protein into oligomers, protofibrils, and insoluble fibrils that form Amyloid-β plaques.
These toxic aggregations choke neural pathways and impair cognition, often surfacing 20–30 years after they begin forming.
.png)
In Alzheimer’s, the crisis starts quietly: Amyloid Beta monomers sometimes misfold and cluster into toxic oligomers and protofibrils, triggering plaque deposits that choke vital neural pathways and devastate cognition.
Our proprietary technology, founded on the visionary work of Prof. Rahimipour, harnesses patented small molecules, a new chemical entity
to create cyclic peptide analogs that targets a unique structure of oligomers (Cross beta-sheet).
This unique structure allows intervention with the formation of small amyloid-β aggregates, including the toxic oligomers.
Our solution is a novel, dual-action cyclic peptide platform. This proprietary technology, founded on the visionary work of Prof. Shai Rahimipour, harnesses patented small molecules, a new chemical entity to create cyclic peptide analogs that target a unique structure of oligomers (Cross beta-sheet).
Solving the BBB Challenge: Unlike large antibody therapies which struggle to penetrate the brain, our small cyclic peptides are structurally engineered for efficient passage across the Blood-Brain Barrier (BBB), ensuring optimal therapeutic concentration at the site of pathology.
Latest company announcements and press coverage
